Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Assembly Biosciences (ASMB) Other Accumulated Expenses: 2015-2025

Historic Other Accumulated Expenses for Assembly Biosciences (ASMB) over the last 6 years, with Sep 2025 value amounting to $5.7 million.

  • Assembly Biosciences' Other Accumulated Expenses rose 20.21% to $5.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $5.7 million, marking a year-over-year increase of 20.21%. This contributed to the annual value of $6.9 million for FY2024, which is 19.46% up from last year.
  • As of Q3 2025, Assembly Biosciences' Other Accumulated Expenses stood at $5.7 million, which was up 68.12% from $3.4 million recorded in Q2 2025.
  • Assembly Biosciences' 5-year Other Accumulated Expenses high stood at $7.3 million for Q4 2022, and its period low was $2.1 million during Q1 2024.
  • Over the past 3 years, Assembly Biosciences' median Other Accumulated Expenses value was $3.9 million (recorded in 2023), while the average stood at $4.2 million.
  • Its Other Accumulated Expenses has fluctuated over the past 5 years, first plummeted by 42.75% in 2021, then rose by 22.62% in 2024.
  • Assembly Biosciences' Other Accumulated Expenses (Quarterly) stood at $6.9 million in 2021, then grew by 6.62% to $7.3 million in 2022, then declined by 21.50% to $5.7 million in 2023, then climbed by 19.46% to $6.9 million in 2024, then grew by 20.21% to $5.7 million in 2025.
  • Its Other Accumulated Expenses stands at $5.7 million for Q3 2025, versus $3.4 million for Q2 2025 and $2.3 million for Q1 2025.